Evidence map›Paper›PMID 35427358›Full record

SynthesisPloS one2022

Prognostic factors for mortality in bullous pemphigoid: A systematic review and meta-analysis.

Xianxia Chen, Yaqiang Zhang, Zhicheng Luo, Yujuan Wu, Taoxiang Niu, Jiayuan Zheng, Yuanyuan Xie

Registry-linked trialOpen access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05984381 (Efficacy and Safety of add-on Dapsone Versus add-on Methotrexate in Patients With Bullous Pemphigoid), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05984381 phase4completednot on this mapstarted 2023, after this paper: background citation

Efficacy and Safety of add-on Dapsone Versus add-on Methotrexate in Patients With Bullous Pemphigoid: A Randomized Controlled Trial

TypeinterventionalSponsorAll India Institute of Medical Sciences, BhubaneswarRan2023 to 2025Enrolled62ConditionsBullous PemphigoidArmsPrednisolone, Dapsone, Methotrexate
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Laryngeal Bullous Pemphigoid: A challenging presentation of a rare disease.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Xianxia ChenDepartment of Dermatology, Lanzhou University Second Hospital, Gansu, China.
Yaqiang ZhangThe 940th Hosptial of Joint Logistics Support force of Chinese People's Liberation Army, Gansu, China.
Zhicheng LuoDepartment of Dermatology, Lanzhou University Second Hospital, Gansu, China.ORCID 0000-0003-3795-8880
Yujuan WuDepartment of Dermatology, Lanzhou University Second Hospital, Gansu, China.
Taoxiang NiuDepartment of Dermatology, Lanzhou University Second Hospital, Gansu, China.
Jiayuan ZhengDepartment of Dermatology, Lanzhou University Second Hospital, Gansu, China.
Yuanyuan XieDepartment of Dermatology, Lanzhou University Second Hospital, Gansu, China.
Lanzhou University Second Hospital · CNPeople's Liberation Army 401 Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo systematically evaluate the prognostic factors for mortality in bullous pemphigoid.

methodsPubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, China Biology Medicine disc and Wanfang Database were searched to collect literature on the prognostic factors for mortality in bullous pemphigoid. The quality of studies was assessed by Newcastle-Ottawa Quality Assessment Scale. Two researchers extracted relevant data and scored study quality independently. The hazard ratio (HR) was calculated using the random effects model. Study heterogeneity was assessed using both Cochran's Q test and I2 statistics. The causes of heterogeneity were assessed by subgroup analysis and/ or sensitivity analysis when heterogeneity was significant. When ten or more studies were included as outcome indicators, publication bias was evaluated by funnel plot and Egger's test.

resultsOut of a total of 1,546 articles retrieved, 15 studies involving 2,435 patients were included. The meta-analysis showed that the mortality of patients with bullous pemphigoid increased with positive bullous pemphigoid 180 antibody (HR = 1.85, 95%CI: 1.25~2.75, P = 0.002); concomitant dementia (HR = 2.26, 95%CI: 1.43~3.59, P<0.001); stroke (HR = 2.09, 95% CI: 1.23-3.55, P = 0.007); heart disease (HR = 1.96, 95% CI: 1.41-2.73, P<0.001) and diabetes mellitus (HR = 2.39, 95% CI: 1.55-3.69, P<0.001). Sex, positive indirect immunofluorescence and hypertension were not associated with prognosis.

conclusionPositive bullous pemphigoid 180 antibody, dementia, stroke, heart disease and diabetes mellitus were the prognostic factors for mortality in bullous pemphigoid.

Indexed as

DementiaHeart DiseasesPemphigoid, BullousStrokeHumansPrognosis

Identifiers

PMID35427358
PMCPMC9012347
OpenAlexW4224011879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.